Myovant Sciences to Host Webcast and Conference Call at 8:30 am Eastern Time Tuesday, June 23 to Discuss Results from Phase 3...
June 22 2020 - 04:05PM
Myovant Sciences (NYSE: MYOV), a healthcare company focused on
redefining care for women and for men, today announced that it will
host a webcast and conference call to discuss top-line results from
the Phase 3 SPIRIT 1 study of once-daily relugolix combination
therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone
acetate 0.5 mg) in women with pain associated with endometriosis.
The webcast and conference call to discuss the data
will be held on Tuesday, June 23, 2020 at 8:30 a.m. Eastern Time /
5:30 a.m. Pacific Time. To participate in the live conference call,
please dial 1-800-532-3746 for domestic callers and +1-470-495-9166
for international callers. A live webcast of the conference
call will also be available on the investor relations page of
Myovant’s website at investors.myovant.com and will remain archived
on Myovant’s website for at least 30 days.
About Myovant Sciences Myovant
Sciences aspires to be the leading healthcare company focused
on redefining care for women and for men. The company’s lead
product candidate is relugolix, a once-daily, oral GnRH receptor
antagonist. The company has three late-stage clinical programs
for relugolix in uterine fibroids, endometriosis, and prostate
cancer. The company is also developing MVT-602, an oligopeptide
kisspeptin-1 receptor agonist, that has completed a Phase 2a study
for the treatment of female infertility as part of assisted
reproduction. Takeda Pharmaceuticals International AG, a
subsidiary of Takeda Pharmaceutical Company Limited, the originator
of relugolix, previously granted the company a worldwide
license to develop and commercialize relugolix
(excluding Japan and certain other Asian countries) and
an exclusive license to develop and commercialize MVT-602 in all
countries worldwide. Sumitovant Biopharma, Ltd., a wholly
owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is the
majority shareholder of Myovant. For more information, please
visit the company’s website at www.myovant.com.
Follow @Myovant on Twitter and LinkedIn.
Investor Contact: Frank Karbe
President and Chief Financial Officer Myovant Sciences, Inc.
investors@myovant.com
Media Contact: Albert Liao
Director, Corporate Communications Myovant Sciences, Inc.
media@myovant.com
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Feb 2024 to Mar 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Mar 2023 to Mar 2024